KFSH&RC's formulary committee recommendation drives NPHC coverage decisions for every GCC Fabry disease treatment, evidence of how concentrated GCC Fabry clinical and access authority actually is.
GCC Fabry disease clinical authority concentrates at King Faisal Specialist Hospital and Research Centre (KFSH&RC). KFSH&RC is the sole laboratory across all six GCC states able to run the HEK293 cell-based assay that confirms migalastat eligibility, with a 6-8 week turnaround for samples sent from elsewhere in the Gulf. Its Fabry disease registry has documented more than 15 unique family clusters sharing GLA mutations, evidence of a national and cross-border referral role that goes well beyond routine clinical management. The infusion network administering enzyme replacement therapy spans King Abdulaziz Medical City (KAMC), KFSH&RC, Al Ain University hospital (AUH), and Hamad Medical Corporation (HMC) in Doha. Our KOL Universe gate (K1) starts by mapping this institutional concentration before any single physician is scored.
That structure changes how AXLRx tiers influence in the GCC. KFSH&RC's metabolic disease team formulary committee recommendation is the channel that drives NPHC coverage decisions for Fabry disease treatments across the region, a gatekeeping role our Tier Classification gate (K2) scores directly, alongside HEK293 assay capability and infusion-network centre status. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live registry publications and institutional roles, then marked Verified, Industry benchmark, or Requires client validation. A commercial team engaging the wrong tier wastes MSL capacity on a physician with no real influence over the NPHC formulary channel, which is exactly what the K1-K6 gate structure is built to prevent.
The GCC Fabry disease institutional network — one gatekeeper, four infusion centres
| Institution | City/Country | Role in Network |
|---|---|---|
| King Faisal Specialist Hospital and Research Centre (KFSH&RC) | Riyadh, Saudi Arabia | Sole GCC HEK293 amenable-mutation assay laboratory; formulary committee recommendation drives NPHC coverage decisions; Fabry disease registry (15+ family clusters) |
| King Abdulaziz Medical City (KAMC) | Riyadh, Saudi Arabia | ERT infusion centre |
| Al Ain University Hospital (AUH) | Al Ain, UAE | ERT infusion centre |
| Hamad Medical Corporation (HMC) | Doha, Qatar | ERT infusion centre |
Sources: KFSH&RC Fabry disease registry 2023; NPHC Fabry disease programme 2023; KFSH&RC genetics laboratory capacity report 2023; Al-Hassnan ZN et al. Saudi Med J 2010.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- KFSH&RC's sole HEK293 assay role and formulary-committee gatekeeping function
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology
- HEK293 assay capability and formulary-committee role as weighting inputs
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live registry and formulary-role cross-checks
- why no placeholder centre ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why single-institution gatekeeping, not scattergun individual outreach, is the variable this workbook sizes first
- Pressure-tested against KFSH&RC's sole HEK293 assay and formulary-committee role before the rest of the workbook is built out
- Every GCC Fabry disease institution sized and sourced from registry and formulary documentation
- KFSH&RC and the named infusion network as the sizing anchor
- Universe boundaries: formulary-committee gatekeeper versus a high-volume infusion centre
- Institutional-influence scoring across HEK293 assay capability and NPHC formulary-committee role
- What separates the Tier 1 gatekeeper from a routine infusion centre
- Influence inputs: registry authorship, assay capability, formulary-committee membership
- Cross-checked against independent registry and NPHC documentation
- Readiness scoring and channel recommendations per institution
- Sequencing implications for MSL deployment
- Territory-to-centre coverage map across Riyadh, the UAE, Doha, and the rest of the GCC
- Where current MSL deployment has gaps
- Multi-market reach for institutions active beyond Saudi Arabia, across the wider GCC
- Implications for coordinated versus purely local engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from published registry data and institutional/formulary documentation, not secondary summaries. No institution or KOL name ships without a verification tag.
GCC Fabry disease KOL sources: KFSH&RC Fabry disease registry 2023, NPHC Fabry disease programme documentation, KFSH&RC genetics laboratory capacity report 2023, and the GCC lysosomal storage disorder network.
- KFSH&RC's sole HEK293 assay role verified against KFSH&RC genetics laboratory capacity report 2023
- Family cluster count verified against KFSH&RC Fabry disease registry 2023
- Infusion-centre network verified against NPHC Fabry disease programme documentation
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging GCC Fabry disease specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.